SecBot SecBot
EFFECT ·Filed Sep 2, 2026

FBRX

Forte Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC9999999995-26-002848
Actionable Insight ▼ Bearish

The effectiveness of two large shelves removes the last procedural barrier to a capital raise. Given the company's cash runway (likely <3 quarters at current burn) and the cross-filing amplifier signal, monitor for a takedown announcement (via 424B5 or 8-K) within the next 30-60 days. Any offering could be highly dilutive given the shelf-to-market-cap ratio.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became effective on September 1, 2026. These shelves, originally filed in June 2026, each register up to $500M in securities, enabling the company to raise capital at any time. With a $1.6B market cap, the combined $1B shelf capacity represents ~63% of current market value, creating a persistent dilution overhang for a clinical-stage biopharma with no revenue and accelerating cash burn ($22.1M net loss in Q1 2026). The cross-filing actuarial verdict confirms this is an amplifier, the shelf effectiveness materially increases near-term equity issuance risk.

Key Facts

  • Two shelf registration statements (333-286226 and 333-256611) became effective on September 1, 2026.
  • Each shelf registers up to $500M in securities (common, preferred, debt, warrants, etc.), for a combined $1B capacity.
  • Forte Biosciences is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026.
  • The $1B shelf capacity represents ~63% of the current $1.6B market cap, signaling substantial potential dilution.
  • The cross-filing actuarial verdict confirms this combo (IPO-context + shelf-context) is an amplifier, supporting an elevated impact score.

Financial Impact

Combined $1B shelf capacity vs $1.6B market cap (~63% potential dilution); company had $58.2M cash and $22.1M quarterly net loss as of Q1 2026

dilutioncash burnequity issuance

Risk Factors

  • Imminent equity offering with significant dilution (~63% of market cap in shelf capacity)
  • Accelerating cash burn ($22.1M quarterly loss) with limited cash runway ($58.2M)
  • Clinical-stage biotech with no approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (FBRX), Batch item 19999999995-26-002848
Document: 9999999995-26-002848-index.html9999999995-26-002844
Document: 9999999995-26-002848.txt9999999995-26-002848
EFFECT Filing (FBRX), Batch item 49999999995-26-002844
Document: 9999999995-26-002844-index.html9999999995-26-002848
Document: 9999999995-26-002844.txt9999999995-26-002848

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Viewing Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026